Lexicon Pharma (LXRX) Tops Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.15 +6.97%
EPS Growth %: -600.0%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -600.0%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $1.25 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Robinhood prices $2B convertible notes offering due 2029
- AXT appoints Tracy Liu to its board of directors
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
